Outcomes in COVID-19 YKYY017 studies

0 0.5 1 1.5+ All studies -150% 1 239 Improvement, Studies, Patients Relative Risk Viral clearance 13% 1 139 RCTs -150% 1 239 Early -150% 1 239 YKYY017 for COVID-19 c19early.org November 2025 FavorsYKYY017 Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) -150% 2.50 [0.10-60.8] progression 1/159 0/80 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk All studies -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk 1 YKYY017 COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors YKYY017 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) -150% 2.50 [0.10-60.8] progression 1/159 0/80 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk All studies -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk 1 YKYY017 COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors YKYY017 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) 31% 0.69 [0.54-0.88] no recov. 70 (n) 69 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.0034 Early treatment 31% 0.69 [0.54-0.88] 70 (n) 69 (n) 31% lower risk All studies 31% 0.69 [0.54-0.88] 70 (n) 69 (n) 31% lower risk 1 YKYY017 COVID-19 recovery result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.0034 Favors YKYY017 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) 13% 0.87 [0.75-1.02] viral load 70 (n) 69 (n) Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.079 Early treatment 13% 0.87 [0.75-1.02] 70 (n) 69 (n) 13% lower risk All studies 13% 0.87 [0.75-1.02] 70 (n) 69 (n) 13% lower risk 1 YKYY017 COVID-19 viral clearance result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.079 Favors YKYY017 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) -150% 2.50 [0.10-60.8] progression 1/159 0/80 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk All studies -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk 1 YKYY017 COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors YKYY017 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) -150% 2.50 [0.10-60.8] progression 1/159 0/80 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Early treatment -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk All studies -150% 2.50 [0.10-60.8] 1/159 0/80 150% higher risk 1 YKYY017 COVID-19 peer reviewed studies c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.58 Effect extraction pre-specified(most serious outcome) Favors YKYY017 Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Wang (DB RCT) -150% 2.50 [0.10-60.8] progression 1/159 0/80 Improvement, RR [CI] Treatment Control Wang (DB RCT) 31% 0.69 [0.54-0.88] no recov. 70 (n) 69 (n) Wang (DB RCT) 36% 0.64 [0.45-0.92] no recov. 65 (n) 69 (n) Wang (DB RCT) 27% 0.73 [0.52-1.04] no recov. 70 (n) 69 (n) Wang (DB RCT) 13% 0.87 [0.75-1.02] viral load 70 (n) 69 (n) Wang (DB RCT) 16% 0.84 [0.67-1.05] viral load 65 (n) 69 (n) Wang (DB RCT) 10% 0.90 [0.74-1.11] viral load 70 (n) 69 (n) YKYY017 COVID-19 outcomes c19early.org November 2025 Favors YKYY017 Favors control